Karin Walker

Directeur/Membre du Conseil chez CYCLACEL PHARMACEUTICALS, INC.

Fortune : 11 106 $ au 31/05/2024

60 ans

Health Technology

Process Industries

Finance

Postes actifs de Karin Walker

Sociétés	Poste	Début	Fin
PROTHENA CORPORATION PLC	Comptroller/Controller/Auditor	20/05/2013	-
CYCLACEL PHARMACEUTICALS, INC.	Directeur/Membre du Conseil	09/11/2020	-
CYCLACEL PHARMACEUTICALS, INC.	Independent Dir/Board Member	09/11/2020	-

Sociétés	Poste	Début	Fin
VINCERX PHARMA, INC.	Directeur/Membre du Conseil	05/03/2020	23/12/2020
VINCERX PHARMA, INC.	Independent Dir/Board Member	05/03/2020	23/12/2020
AFFYMAX, INC.	Comptroller/Controller/Auditor	02/10/2012	01/05/2013
AMYRIS, INC.	Comptroller/Controller/Auditor	01/01/2009	01/09/2012
CV Therapeutics, Inc. CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases	Comptroller/Controller/Auditor	01/06/2006	01/08/2009
Ernst & Young US LLP Ernst & Young US LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young US LLP was engaged in providing accounting services. The company was headquartered in Pittsburgh, PA.	Corporate Officer/Principal	-	-

California Polytechnic State University (San Luis Obispo)

Undergraduate Degree

Internationale

Etats-Unis	8
Irlande	2

Opérationnelle

Comptroller/Controller/Auditor	4
Director/Board Member	2
Independent Dir/Board Member	2

Sectorielle

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	4
AFFYMAX, INC.	Health Technology
PROTHENA CORPORATION PLC	Health Technology
AMYRIS, INC.	Process Industries
CYCLACEL PHARMACEUTICALS, INC.	Health Technology

Entreprise privées	3
CV Therapeutics, Inc. CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases	Health Technology
LifeSci Acquisition Corp. LifeSci Acquisition Corp. Financial ConglomeratesFinance LifeSci Acquisition Corp. operates as a blank check company. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The company was founded on December 19, 2018 and is headquartered in New York, NY.	Finance
Ernst & Young US LLP Ernst & Young US LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young US LLP was engaged in providing accounting services. The company was headquartered in Pittsburgh, PA.	Commercial Services